In Brief
This article was originally published in The Tan Sheet
Executive Summary
Health Canada warns of benzocaine risk; Perrigo first with store-brand Mucinex; NAD enters Glaxo/Colgate toothpaste war; Sun Capital snags supplement manufacturer CornerStone; more news In Brief.
You may also be interested in...
NARB Upholds NAD Recommendations For Colgate Sensitive Ads
The Council of Better Business Bureaus appeals board agrees that testing does not support claims that Colgate Sensitive Pro-Relief is “faster” and “better” than GlaxoSmithKline's Sensodyne. Colgate argued its studies were sufficient, having incorporated industry-standard methodology accepted by FDA and the ADA.
Colgate Bids To Expand U.S. Toothpaste Lineup Through FDA Rulemaking
Colgate seeks regulatory approval for a version of its Colgate Sensitive Multi-Protection toothpaste in a formulation it already markets internationally. The request made in a citizen petition comes after Colgate’s plan to expand its U.S. toothpaste business failed when FDA did not give approval for Sensitive Pro-Relief.
Perrigo Sets Generic Mucinex Launch After Patent Claim Decision
The private labeler clears a Reckitt Benckiser legal hurdle and will launch generic Mucinex (guaifenesin) by April. Watson has filed ANDAs for three Mucinex products and could be a good strategic partner for Perrigo, an analyst suggests.